



Vicore resolves on a set-off issue of 87,686 shares as part of milestone compensation

- Milestone compensation to collaboration partners in connection with the first patient dosed with C106.
- One-time payment to the company's collaboration partners Emeriti Bio and HaLaCore Pharma in a total of approximately 6 MSEK, of which 3 MSEK in cash compensation and 87,686 newly issued shares in Vicore corresponding to approximately 3 MSEK.

Gothenburg, June 17, 2022 - Vicore Pharma Holding AB (publ) ("Vicore"), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2 receptor (AT2R), has today resolved on a set-off issue of 87,686 shares and cash payment of 3 MSEK to collaboration partners for the start of the phase 1 trial with C106.

In connection with the first patient being dosed, Emeriti Bio and HaLaCore Pharma will together receive a one-time payment of a total of approximately 6 MSEK, split between 3 MSEK in cash and 87,686 newly issued shares in Vicore corresponding to approximately 3 MSEK. The board has therefore today resolved on a new issue of 87,686 shares directed to Emeriti Bio and HaLaCore Pharma.

The share issue is carried out with deviation from the shareholders' preemption rights based on the authorization from the Annual General Meeting on May 11, 2022. Payment is made by set-off of a claim against the company. The number of shares is based on a share price of 34.21 SEK per share, which corresponds to the volume-weighted average share price during the five last trading days prior to dosing of the first patient (June 8, 2022 up to and including June 14, 2022). The share issue will result in an increase in the number of shares in Vicore of 87,686 shares, from 71,760,293 to 71,847,979. The share capital will increase by approximately 43,843.00 SEK, from approximately 35,880,147.15 SEK to approximately 35,923,990.15 SEK. The share issue implies a dilution of approximately 0.12 percent based on the total number of shares in Vicore after the consummation of the share issue.

For further information, please contact:

Hans Jeppsson CFO

Phone: +46 70 553 14 65

E-mail: hans.jeppsson@vicorepharma.com

This information was submitted for publication, through the agency of the contact person set out above, on June 17, 2022 at 10:30 CET.

About Vicore Pharma Holding AB (publ)

Vicore is a clinical-stage pharmaceutical company focused on developing innovative medicines in severe diseases where the Angiotensin II type 2 receptor (AT2R) plays an important role. The company currently has four development programs, VP01, VP02, VP03 and VP04. VP01 aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis (IPF), pulmonary artery hypertension (PAH) and COVID-19. VP02 is a new formulation and delivery route of thalidomide and focuses on the underlying disease and the severe cough associated with IPF. VP03 includes the development of new AT2 receptor agonists. VP04 develops a clinically validated digital therapeutic for IPF patients.



The company's shares (VICO) are listed on Nasdaq Stockholm's main market. For more information, see www.vicorepharma.com.